Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Truthfan,
Did you notice what Battelle was doing with the $149m fund? It was something related to small peptide, Liquid Chromatography with Tandem Mass Spectrometry, and enzyme-linked immunospot (ELISPOT) assay, which makes me have fantasy.
https://www.battelle.org/insights/newsroom/press-release-details/battelle-amplifybio-andelyn-biosciences-win-research-contract-for-national-institute-of-neurological-disorders-and-stroke
https://govtribe.com/award/federal-idv-award/indefinite-delivery-contract-75n95022d00021
How long have you been roaming on this board? 12 years?
I don't mean to brag. But holding this ticker for about three years, I know a lot better than you. I think the reason could be you are hired by someone so you have no motivation to study hard and dig deeper.
Ned,
Now you know the colorectal trial is real, don't you?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174356517
Be prepared that RevImmune most likely could have a bunch of secret trials.
Thanks for the post!
I assume you have champagne ready for the celebration!
In the PR in 2016 on the collaboration trial between Merck and NWBO, LP said the trial took more than 2 years of planning and work. The PI of the collaboration trial was Markus Moehler. I went through some of his publications between 2013 and 2023 to see if he had been in contact with Merck. I suspect if there are still some people who claimed that this trial never happened. The collaboration between Markus Moehler and Merck reminds me of the interaction between Vivek Subbiah and NWBO.
Or you can simply wait.
By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?
It could be Merck or NCI. Did you see that Merck had massive construction of biologic manufacturing facilities at West Point campus and yet no even a word can be found in its 10k about those facilities?
Ned,
You must have a sense of achievement. You along with the dark forces put the company in the current circumstance. But beware, this company will have a big revival.
See this results on pediatric patients from the combination of DCVax-L with CYT107. You don't want DCVax-L available to all cancer patients including children, do you? How could you sleep at night?
Doc logic,
I think you knew this. J. Kelly Ganjei has been the board member of INmune Bio Inc for many years. INmune Bio Inc has trials on both cancer and Alzheimer which strike me as two completely different fields. Is Alzheimer an autoimmune disease?
https://www.inmunebio.com/index.php/about-us
This never gets old. So I list the patent here again.
https://patents.google.com/patent/US20150202291A1/en
Current Assignee: RevImmune Inc; University of California; Northwest Biotherapeutics LLC; Cognate Bioservices Inc
NCI did the trial using DCVax-L combined with CYT107. I would not be surprised that RevImmune as a solely private-owned company and the owner of the patent uses this above combination to do some clinical trials on other targets.
If envy was not a sin, I would envy you.
Congrats on loading at such low price.
ILT,
Really appreciate your reply.
Every long was excited seeing Kristyn Power liked Matthew Vandermast's post.
https://www.linkedin.com/feed/update/urn:li:activity:7173690886331990018/
They should be more excited to see the director of technology transfer from Takeda liked Vikas Moolchandani's post. That's also one of the reasons that I said there would be no BO.
But during the past ten years, there was a certain time interval the sp was less than 20 cents. The first poly-iclc trial results were published in 2011. The second one had the abstract published in 2015 if I am not mistaken. From science perspective, those results indicated back then that DCVax-L is amazing. Especially for the second one, the presentation over ten years ago already showed that with only six patients (the objective is 20 patients) enrolled in the poly-iclc group the conclusion can be drawn already. I believe all the longs were attracted to this company purely by science, were they not? That's why I thought a lot of longs would load a lot when sp was around teens. Did I hurt someone long's feeling? If I did, my apologies.
Take everything I posted with the biggest grain of salt.
2. We are on the eve of approval , with clear indication it will be followed with a swift NICE recommendation to the NHS .
>>How could you know the recommendation is swift? Did you get the idea from the following document?
https://www.england.nhs.uk/wp-content/uploads/2023/12/23-25NHSPS-amendment-consultation-annex.xlsx
3. Licensing deals are place holders for large pharma.
>> You don't think every long knows this?
4. Large pharma know the precise value of every thing the company has achieved to date , the future potential market share
and that there will be several suitors interested .
>> Of course large pharma knows the value. They knew it when Dr. Liau published the results on the combination trial which was in 2011. You didn't realize Merck already formed partnership with some of the companies which provided the research tools that Dr. Liau employed around the publication time, did you?
5. One will , if they haven't already pen a deal with us that is either buyout or a far larger licensing deal than you`d expect to give them the first call on buy out ( placeholder )
>> Please say something not obvious.
6. Manufacturing and scaling is done .
>> Where is the evidence? Any idea which company provides the possible technology adopted in flaskworks that isolates dendritic cells intact?
7. I strongly suspect a buyout offer price has been touted to all interested parties during ` licensing ` discussions to which they all appeared indifferent but one will return and pay up ( $10bn / $8pps )
>> Well, don't put your hope on BO. There will be no BO. NWBO is going to have partnership with the government and private sectors. A treatment as revolutionary as DCVax-L must be a cornerstone in the Moonshot program. You still haven't realized the significance of this paper.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249282
8. Merck BMY ... maybe JNJ ... they`re all playing a game of chicken, but one will pull the trigger early , I suspect on approval which LP will of course commute to them before she PR's it to us.
>> Give us some indications why you chose these companies.
Now you can join my ignore list which only has that legend poster.
Too much ego
Congrats on holding for such a long time. I think you loaded a lot when sp was in teens.
I root for BO. But when I take a look at the deal between Merck and Prometheus. I simply cannot see the possibility of BO.
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Splash-Investor-Event-Slides-FINAL-1.pdf
Any BP which has both ADCs and t-cell engagers in their program will have a partnership with NWBO sooner or later. They need a platform to tell them what are targets once loaded on their ADCs ro t-cell enagers that can trigger intense anti-tumor response.
You never read the paper, right? As a matter of fact, the stuff you put here shows us from one perspective the very fact that NWBO is light years ahead of all those vaccines. They are still in a maze trying to figure out which could be the possible exit while NWBO is on a high speed train track.
Next time, read the stuff before you post it, which makes you look smart. Now read the following part first.
https://www.medrxiv.org/content/10.1101/2023.03.12.23287108v1
ILT,
I am not an expert on AI stuff. But I do agree with you. If AI can beat a real pilot in dog fight, sniffing out naked shorts by AI sounds a lot easier.
Do you have any idea about the number of clinical trials on GBM? Over one thousand. GBM is most likely the toughest target. It is great LP first conquered the Mount Everest in cancer. You still haven't realized it is LP who made Merck pit against BMS to get the best deal.
You think my posts are delusional? Have you read any peer-reviewed papers? Maybe it is too much for you. How about this? Did you read carefully the Nature preprint? Most likely not. Do you know why all the BPs suddenly rekindled their interests in ADCs and t-cell engagers?
The possible merger or some other types of partnership with Oncovir couldn't be more obvious.
When did this acquisition and exit lawyer join Oncovir? June 2022.
This management team has been working on DCVax-L for over 20 years. No other management team knows better than them. Plus, younger management team comes into shape. You can save your Wall street BS doctrine for other mediocre companies.
Ned,.
I like this name better.
Is it deliberate that you didn't mention this one?
https://aacrjournals.org/clincancerres/article/17/6/1603/12140/Gene-Expression-Profile-Correlates-with-T-Cell
Sounds like you read many of my posts.
Let me clear your mind about 200 patients in three months.
See this video? Les Goldman went to the Big Biz Show on August if I remember correctly and he said about 800 patients receiving DCVax. At the beginning of June, Dr. Bosch mentioned in his presentation that 600 patients went through the treatment. Is there any problem about the number of 200?
beartrap12,
Thanks for the post.
My speculation is that the approval could be about DCVax-L + poly-iclc based on RWD/RWE with guidance about the combination concerning keytruda. There is no SEC requirement about public disclosure of drug application. I suspect the approval should come from FDA and EU too. But this thought could be my fantasy.
Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2734629
You forgot who nailed Nemesis18. If any one of my dot connecting becomes real, you will be nailed too.
George,
Keytruda is an approved drug. I don't mean the filing package is about combo. What I mean is that RAs grant approval of DCVax-L and in the meantime give the guidance about the combination.
Do you have commonsense? GBM is one of the most life-threatening diseases, if not the most one. Now in UK, the occurrence rate is two or three times higher than it used to be. Each month probably plenty GBM patients filed for compassionate use program and you are talking about NICE reimbursement in 90 days.
See this consultation survey with DCVax-L included? It ends on January 26, 2024. Most likely NICE has the payment scheme setup immediately after the MHRA approval.
He still pays you, right? Each weekend, that dude likes all his minions' posts sending the message: big brother is watching you all.
Have fun while you can. But keep in mind the longs have the last laugh!
Or Novamune?
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594622/
I don't see why it is speculative. It seems to me at minimum the approval is about DCVax-L combined with poly-iclc. The trial about poly-iclc was started over 20 years ago. From the compassionate case #1, clearly poly-iclc was adopted in the compassionate use program starting in January 2016, which I have been saying for months. By now, there are at least hundreds of patients who received the treatment.
Did Nice sign a contract with Flatiron about RWD/RWE in 2020? It seems reasonable that NICE certainly should collect data from those compassionate use cases. In fact, the real speculative part we should talk about is whether keytruda was included in the package. IMO, it should be. The last patient for the combo trial was enrolled in June 2021. By the end of last year, it has been over two years. Not many rGBM patients can survive over two years. In UK, for compassionate use, doctors have the discretion to choose whatever the best treatment is fit for the patients. I would not be surprised if keytruda was included for some compassionate patients. Did Dr. Liau's colleague mention that the definition of phase doesn't matter what it matters is the efficacy? We can see that in the poly-iclc trial as mentioned in the Nature preprint, the original plan was to enroll 60 patients with 20 patients for each of the three groups. But with five patients in placebo and nine patients in each of the two experimental groups respectively, objectives were reached, which is perfect illustration of efficacy.
The extra pages beartrap mentioned about could be the biomarker data for many patients. That's my conjecture.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237562
https://clinicaltrials.gov/study/NCT00068510
https://aacrjournals.org/clincancerres/article/17/6/1603/12140/Gene-Expression-Profile-Correlates-with-T-Cell
Did you let Adam use your account? How much did he pay you?
Which one? US government? Merck? Amgen?
IC,
Adam Fraudstein is a political science major. He can only repeat the hit piece supplied by the dark forces. You are repeating what he told you, are you not? How often do you reach him now? The more I see your nonsense, the more I feel you are channeling Adam.
Here is my conjecture on the list of the critical partners. Merck, Amgen, AZN, Roche, Takeda, Sanofi. I can add more.